Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (1229)	3/7/2000 10:19:00 PM
From: Greg Jung	Respond to of 1972

I've been reading about it off and on in the washington post. twp.com and I believe it has search capability on the archive.

To: David Bogdanoff who wrote (1229)	3/8/2000 8:39:00 PM
From: William Strop	Read Replies (1) \| Respond to of 1972

Dave, Here is some stuff I posted earlier. Call up Alan Engbring for more details. b ********* I agree with your view. The FDA has to be concerned after the PA. death, step up monitoring, etc..., otherwise they aren't doing their job. Regarding that subject, the WSJ (Friday, 3/3/2000) has an article re: the Vascular Genetics trials. Good reading for everyone with quotes from Vascular Genetics & Human Genome Sciences. Jeffrey Isner, chief researcher, was quoted as saying, "I am looking forward to the opportunity to present the results of these trials in two weeks, and at that time I believe the safety & efficacy will be more than apparent". I think he will be reporting sometime the week of 3/12/2000. *********